An open-label, controlled, multi-site, interventional, 2-arm, Phase II trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed cel...
- Carcinoma
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Papilloma
- Recurrence
Age: 18 years - 66+
Gender: All